Liquid biopsy can be contemplated for molecular profiling when conventional tumor biopsy is not available or to monitor emergent mutations of resistance to targeted therapy, especially prior to re-challenge with anti-epidermal growth factor receptor (anti-EGFR) treatment, although this has yet to be approved by our national authorities [II, B] [15]. This evidence concerns the gene EGFR and neoplasm.